Cargando…

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs

BACKGROUND: The Global Polio Eradication Initiative plans for coordinated cessation of oral poliovirus vaccine (OPV) use, beginning with serotype 2-containing OPV (i.e., OPV2 cessation) followed by the remaining two OPV serotypes (i.e., OPV13 cessation). The risk of circulating vaccine-derived polio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duintjer Tebbens, Radboud J., Thompson, Kimberly M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4582727/ https://www.ncbi.nlm.nih.gov/pubmed/26404780 http://dx.doi.org/10.1186/s12879-015-1114-6

Ejemplares similares

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy
por: DUINTJER TEBBENS, R. J., et al.
Publicado: (2017)

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2017)

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Another look at silent circulation of poliovirus in small populations
por: Kalkowska, Dominika A., et al.
Publicado: (2018)

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

How should we prepare for an outbreak of reintroduced live polioviruses?
por: Thompson, Kimberly M, et al.
Publicado: (2017)

Circulating Vaccine Derived Poliovirus and the polio eradication endgame
por: Davis, Robert, et al.
Publicado: (2012)

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination
por: Kalkowska, Dominika A, et al.
Publicado: (2015)

Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission
por: Thompson, Kimberly M., et al.
Publicado: (2017)

An economic analysis of poliovirus risk management policy options for 2013–2052
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame
por: Pons-Salort, Margarita, et al.
Publicado: (2016)

Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2019)

Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians’ perspectives in the endgame plan for polio eradication
por: Galal, Nermeen M., et al.
Publicado: (2018)

The role of a genetically stable, novel oral type 2 poliovirus vaccine in the poliomyelitis endgame
por: Costa Clemens, Sue Ann, et al.
Publicado: (2023)

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame
por: Parker, Edward PK, et al.
Publicado: (2015)

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2018)

Review of use of inactivated poliovirus vaccine in campaigns to control type 2 circulating vaccine derived poliovirus (cVDPV) outbreaks()
por: Estivariz, Concepcion F., et al.
Publicado: (2023)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

Recombination between Polioviruses and Co-Circulating Coxsackie A Viruses: Role in the Emergence of Pathogenic Vaccine-Derived Polioviruses
por: Jegouic, Sophie, et al.
Publicado: (2009)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar
por: Razafindratsimandresy, Richter, et al.
Publicado: (2018)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Recombinant Vaccine–Derived Poliovirus in Madagascar
por: Rousset, Dominique, et al.
Publicado: (2003)

Vaccine–derived Poliovirus, Thailand, 2003
por: Tharmaphornpilas, Piyanit
Publicado: (2005)

Achieving High Poliovirus Antibody Seroprevalence in Areas at Risk of Vaccine-Derived Poliovirus Transmission—Niger Experience
por: Ousmane, Sani, et al.
Publicado: (2021)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines
por: Alipon, SweetC B, et al.
Publicado: (2022)

Potential Future Use, Costs, and Value of Poliovirus Vaccines
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Circulation of Type 2 Vaccine-Derived Poliovirus in China in 2018–2019
por: Zhao, Hehe, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tfl3irrq6kc74ridtngd2ciejl